NuVasive price target raised to $51 from $48 at Truist

Truist raised the firm’s price target on NuVasive to $51 from $48 and keeps a Hold rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.